职称：副教授

学历：博士

E-mail:[email protected]

研究方向：溶瘤II型单纯疱疹病毒抗肿瘤临床前及临床研究；新型溶瘤病毒药物开发及生物标志物探索；溶瘤病毒联合CAR-T抗肿瘤的分子机制研究

工作经历：

国家公派美国马里兰大学医学院联合培养博士，副教授，博士生导师，湖北省“双创战略团队”核心成员，湖北工业大学“南湖学者”学术骨干。主持/参与国家自然科学基金青年基金、湖北省教育厅青年项目、国家重大新药创制科技重大专项、湖北省重点研发计划及企业横向课题十余项。在Annals of Medicine, Human Gene therapy, Journal of Medical Virology, BBA-Biomembranes, Virology Journal等杂志发表研究论文20余篇。主讲《生物化学》、《生物制药工艺学》、《病毒学》等主干课程。

2017/10-至今，湖北工业大学，老王论坛 ，讲师、副教授

荣获奖励：

1.第十届中国国际大学生创新大赛全国金奖，指导教师；

2.2019、2024年湖北工业大学年度考核优秀；

3.2022年湖北工业大学考研优秀班导师；

4.2020年“雁临”优秀青年教师。

部分研究课题：

1.国家自然科学基金青年基金，82001758，30万，2021.01-2023.12，主持；

2.湖北省教育厅青年人才项目，Q20201403，2万，2020.01-2021.12，主持；

3.湖北省重点研发计划，2020BCA062，200万，2020.06-2022.12，参与；

4.企业横向，ZRS20242260，50万，2025.01-2026.12，主持；

5.企业横向，ZRS20230971，50万，2024.01-2024.12，主持。

代表性研究论文：

1.Zheng Xiaodi; Liu Biao; Ni Peng; Cai Linkang; Shi Xiaotai; Ke Zonghuang; Zhang Siqi; Hu Bing; Yang Binfeng; Xu Yiyan; Long Wei; Fang Zhizheng; Wang Yang; Zhang Wen; Xu Yan; Wang Zhong; Pan Kai; Zhou Kangping; Wang Hanming; Geng Hui*;Hu Han*; Liu Binlei; Development and application of an uncapped mRNA platform. Annals Of Medicine,2025, 57(1):2437046;

2.Wang Xuan; Tian Hui; Chi Zhihong; Si Lu; Sheng Xinan;Hu Han; Gu Xiangyong; Li Siming; Li Caili; Lian Bin; Zhou Li; Mao Lili; Tang Bixia; Yan Xieqiao; Wei Xiaoting; Li Juan; Liu Binlei; Guo Jun; Kong Yan; Cui Chuanliang; Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights. Journal for ImmunoTherapy of Cancer,2025, 13(2):e10662

3.Hu Han^#; Cheng Yining^#; Cao Jinjin; Guo Yujie; Duan Haixiao; Jin Yuling; Zhang Lingfang; Wang Yang; Liu Binlei; Development of taqman-based real-time PCR based on ψ gene for quantitative detection of CAR-T cells. Analytical Biochemistry,2024:115626

4.Hu Han^#; Zhang Siqi^#; Cai Linkang; Duan Haixiao; Li Yuying; Yang Junhan; Wang Yang; Liu Biao; Dong Shuang; Fang Zhizheng; Liu Binlei; A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with Interleukin-12, Interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy. Virology Journal,2022, 19(1):74

5.Hu Han^#; Zhang Ziyi^#; Wang Runyang; Wang Yang; Jin Jing; Cai Linkang; Yang Junhan; Duan Haixiao; Wu Zhen; Fang Zhizheng; Liu Binlei; BGC823 cell line with the stable expression of IRFP720 retains its primary properties with promising fluorescence imaging ability. DNA And Cell Biology,2020, 39(5):900-908

6.Hu Han; Di Bin; Tolbert W. David; Gohain Neelakshi; Yuan Weirong; Gao Pan; Ma Bohan; He Qigai; Pazgier Marzena; Zhao Le; Systematic mutational analysis of human neutrophil α-defensin HNP4. Biochimica et Biophysica Acta (BBA)-Biomembranes,2019, 1861(4):835-844

7.Hu Han; Guo Nan; Chen Shuhua; Guo Xiaozhen; Liu Xiaoli; Ye Shiyi; Chai Qingqing; Wang Yang; Liu Binlei; He Qigai; Antiviral activity of piscidin 1 against pseudorabies virus bothin vitroandin vivo. Virology Journal,2019, 16(1):95

8.Wang Yang^#; Wang Runyang^#;Hu Han^#; Jin Jing; Cai Linkang; Zhang Siqi; Yi Fan; Li Yanxia; Zheng Zhiqiang; Zhou Qin; Fang Zhizheng; Liu Binlei; Preclinical safety assessment of an oncolytic herpes simplex virus type 2 expressed PD-L1/CD3 bispecific antibody. International Immunopharmacology,2023, 124:110975

9.Cai Linkang^#;Hu Han^#; Duan Haixiao; Li Yuying; Zou Zongxing; Luo Kailun; Zhang Ziyi; Yang Junhan; Jin Jing; Chen Ying; Ke Zonghuang; Fang Zongyao; Liu Qiong; Hong Xiaoqian; Hu Sheng; Liu Binlei; The construction of a new oncolytic herpes simplex virus expressing murine Interleukin-15 with gene-editing technology. Journal of Medical Virology,2020, 92(12):3617-3627

10.Wang Yang^#; Zhou Xiaobing^#; Wu Zhen^#;Hu Han^#; Jin Jing^#; Hu Yanping; Dong Yuting; Zou Jianwen; Mao Zeyong; Shi Xiaotai; Huo Yan; Lyu Jianjun; Fang Zhizheng; Zhang Wen; Zhu Yujie; Li Bo; Liu Binlei;Preclinical safety evaluation of oncolytic herpes simplex virus type 2. Human Gene Therapy,2019, 30(5):651-660

11.Wang Yang; Jin Jing; Li Yuying; Zhou Qin; Yao Ruoyi; Wu Zhen;Hu Han; Fang Zzhizheng; Hu Sheng; Liu Binlei; NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors. Translational Research,2022, 240:64-86

12.Zheng Yi; Wang Xiaomin; Ji Qiang; Fang Aizhong; Song Lairong; Xu Xiaoying; Lin Yi; Peng Yichen; Yu Jianyu; Xie Lei; Chen Feng; Li Xiaojie; Zhu Sipeng; Zhang Botao; Zhou Lili; Yu Chunna; Wang YaLi; Wang Liang;Hu Han; Zhang Ziyi; Liu Binlei; Wu Zhen; Li Wenbin; OH2 oncolytic virus: a novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses. Cancer Letters,2024, 589:216834

参编学术专著：

1.史劲松、陈平、李会主编，《生物制药工艺学》，化学工业出版社，2024，ISBN(978-7-122-44967-2)。